Mantle Cell Lymphoma clinical trials in Maryland
15 active Mantle Cell Lymphoma trials with a site in Maryland. Describe your situation to see which ones look like a fit.
- Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
- A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
- DALY II USA/ MB-CART2019.1 for DLBCL
- A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
- Vaccine Responses in Patients With B Cell Malignancies
- CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
- Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event
- A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.